Target intelligence / Profile preview

Hydroxymethylglutaryl-CoA Reductase (None)

Target: None
Molecular classification: Enzyme

Overview

HMG-CoA reductase (HMGCR) is a key enzyme in the mevalonate pathway, catalyzing the conversion of HMG-CoA to mevalonate. It is the rate-limiting step in cholesterol synthesis and is a primary target for statin drugs to lower LDL cholesterol and reduce cardiovascular risk.

Other names: HMG-CoA reductase3-hydroxy-3-methylglutaryl-coenzyme A reductaseHMGCR

Mechanism of action

Competitive inhibition

Biological functions

Cholesterol biosynthesisIsoprenoid biosynthesisLipid metabolism regulationSterol regulationCellular homeostasis

Disease associations

Cardiovascular diseaseDyslipidemiaHyper-lipoproteinaemiaMultiple sclerosisMyocardial infarctionPain

Interacting drugs

Statins

Beyond the preview

Go deeper on Hydroxymethylglutaryl-CoA Reductase (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydroxymethylglutaryl-CoA Reductase (None).

Explore the full profile